Hereditary hemochromatosis due to ferroportin-gene mutations; significance for hepcidin measurement as screening tool?;Primaire hemochromatose door ferroportinegenmutaties: Is er een plaats voor hepcidine in de diagnostiek?

Nederlands Tijdschrift voor Klinische Chemie en Laboratoriumgeneeskunde

Volumn 36, Issue 1, 2011, Pages 6-11

  Van Wijngaarden, P ^a   Hoskam, J ^a   Koeken, A ^a   Boer, J M A ^b   Swinkels, D W ^c   Ermens, A A M ^a   Cobbaert, C M ^d  

^a AMPHIA HOSPITAL   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Ferroportin N144h gene mutation; Hemochromatosis; Hepcidin

Indexed keywords

FERRITIN; FERROPORTIN; HEPCIDIN; HFE PROTEIN;

ARTICLE; DIAGNOSTIC KIT; FERRITIN BLOOD LEVEL; GENE FUNCTION; GENE MUTATION; GENETIC DISORDER; HEMOCHROMATOSIS; HUMAN; IRON OVERLOAD; MALE; MUTATIONAL ANALYSIS; NETHERLANDS; PRACTICE GUIDELINE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

EID: 79951546926     PISSN: 15708306     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pietrangelo A. Hereditary hemochromatosis - a new look at an old disease. N Engl J Med. 2004; 350: 2383-97.
2. http://www.nvkc.nl/kwaliteitsborging/documents/ richtlijnhemochromatosedefinitief2007.pdf
3. Elmlinger MW et al. Reference ranges for serum concentrations of LH, FSH, E2, prolactin, progesterone, SHBG, DHEAS, cortisol and ferritin in neonates, children and young adults. Clin Chem Lab Med. 2002; 40: 1151-60.
4. IFCC, Schumann G et al. IFCC primary reference procedures for the measurement of the catalytic activity concentrations of enzymes at 37 degrees C. Clin Chem Lab Med. 2006; 44 (9): 1146-55.
5. Stott MK, Fellowes AP, Upton JD, Burt MJ, George PM. Simple multiplex PCR for the simultaneous detection of the C282Y and H63D hemochromatosis (HFE) gene mutations. Clin Chem. 1999; 45: 426-8. (Pubitemid 29114186)
6. Koeken A, Schrauwen L, de Baar E, Cobbaert C. Hemochromatosis detection in the Breda region - an updated diagnostic strategy. Ned Tijdschr Klin Chem Labgeneesk. 2004; 29: 58 (Abstract).
7. Kroot JJ, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, Peters HP, et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem. 2010; 56 (10): 1570-9.
8. Swinkels DW, Jorna AT, Raymakers RA. Synopsis of the Dutch multidisciplinary guideline for the diagnosis and treatment of hereditary haemochromatosis. Neth J Med. 2007; 65: 452-5.
9. Swinkels DW, Marx JJM. Diagnostiek en behandeling van primaire hemochromatose. Ned Tijdschr Geneeskd. 1999; 143: 1404-8. (Pubitemid 29325362)
10. Bergmans JPH, Stalenhoef AFH, Marx JJM, Janssen MCH, Swinkels DW, Jacobs EMG, Kemna EHJM. Hereditaire hemochromatose: nieuwe genen, nieuwe ziekten en hepcidine. Ned Tijdschr Geneesk. 2007; 151: 1121-7. (Pubitemid 47040763)
11. Njajou OT, Vaessen N, Joosse M, Berghuis B, van Dongen JW, Breuning MH, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet. 2001; 28: 213-4. (Pubitemid 32626019)
12. Montosi G, Donovan A, Totaro A, Garuti C, Pignatti E, Cassanelli S, Trenor CC, Gasparini P, Andrews NC, Pietrangelo A. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest. 2001; 108: 619-23. (Pubitemid 32777742)
13. Mayr R, Janecke AR, Schranz M, Griffiths WJH, Vogel W, Pietrangelo A, Zoller H. Ferroportin disease: a systematic meta-analysis of clinical and molecular findings. J Hepatology 2010; 53 (5): 941-9.
14. De Domenico I, Ward DM, Musci G, Kaplan J. Iron overload due tot mutations in ferroportin. Haematologica 2006; 91: 92-5. (Pubitemid 43235391)
15. Dijk BAC van, Laarakkers CMM, Klaver SM, Jacobs EMG, Tits LJH van, Janssen MCH, Swinkels DW. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. Br J Haematol. 2008; 142: 979-85.
16. Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis. 2004: 32; 131-8. (Pubitemid 38147710)
17. Drakesmith H, Schimanski LM, Ormerod E, Merryweather-Clarke AT, Viprakasit V, Edwards JP, Sweetland E, Bastin JM, Cowley D, Chinthammitr Y, Robson KJ, Townsend AR. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood. 2005; 106: 1092-7. (Pubitemid 41076459)
18. Lee PL, Beutler E. Regulation of hepcidin and iron-overload disease. Annu Rev Pathol. 2009; 4: 489-515. Review.
19. Oates PS. The role of hepcidin and ferroportin in iron absorption. Histol Histopathol. 2007; 22: 791-804. (Pubitemid 47034145)
20. Nemeth E. Ferroportin mutations: a tale of two phenotypes. Blood. 2005; 105: 3763-4. (Pubitemid 40656113)
21. Papanikolaou G, Tzilianos M, Christakis JI, Bogdanos D, Tsimirika K, MacFarlane J et al. Hepcidin in iron overload disorders. Blood. 2005; 105: 4103-5.
22. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood. 2005; 106: 3710-7. (Pubitemid 41739004)
23. Sham RL, Phatak PD, Nemeth E, Ganz T. Hereditary hemochromatosis due to resistance to hepcidin: high hepcidin concentrations in a family with C326S ferroportin mutation. Blood. 2009; 114: 493-4.
24. Sham RL, Phatak PD, West C, Lee P, Andrews C, Beutler E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. Blood Cells Mol Dis. 2005; 34: 157-61. (Pubitemid 40250491)